Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07326631

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
College of Physicians and Surgeons Pakistan · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Conditions

Interventions

TypeNameDescription
DRUGFinerenoneTo assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Timeline

Start date
2026-01-01
Primary completion
2026-06-30
Completion
2026-07-01
First posted
2026-01-08
Last updated
2026-01-08

Source: ClinicalTrials.gov record NCT07326631. Inclusion in this directory is not an endorsement.

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure (NCT07326631) · Clinical Trials Directory